Clinical Trial Search

Primary: Absolute Change From Baseline in Hemoglobin (Hgb) to End of Treatment (Week 6) — 9.46; 9.93; 9.86; 9.67 Grams per deciliter (g/dL) — p=<0.0001

Primary: Treatment 1-6 and Unintentional Dosing Arms: Percentage of Participants With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load Greater Than 5.27…

Primary: Percentage of Participants Achieving a Successful Hemoglobin Response — 54.9; 10.3 Percentage of participants — p==0.0001

Primary: Stroop Color and Word Test Score — 31.17; 28.89; 32.87; 30.69 number of correct responses

Primary: Number of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) >=50 Copies/Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Category at Week 48 — 1…

Primary: Dose Escalation: Maximum Tolerated Dose (MTD) of Tislelizumab — NA mg

Primary: 1 Hour Pain Assessment Numeric Rating Scale During Rest — 5; 5 units on a scale — p=.87

Primary: Number of Grade 3 or 4 Adverse Events, Highest Occurrence Per Participant — 1; 0; 0; 0 Adverse events

Primary: Percentage of Treatment Responders at Months 12 and 24 — 64.1; 50.0; 67.5; 58.5 percentage of participants

Primary: Response Rate (RR) — 4.8; 0 percentage of participants

Primary: Substudy 1: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 — 0; 8.5; 14.3; 13.5 percentage of participants — p=0.049

Primary: Change in Knee Pain — -0.93; -0.72; -0.93; -0.71 score on a scale — p=0.004

Primary: Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 16 — -0.02; -0.49; -0.91; -1.03 Percent — p=0.0071

Primary: Blood Glucose Level — 172.39; 212.85; 164.47; 191.25 mg/dL

Primary: Changes in Combined Positive Scoring (CPS) in Non-irradiated Sites Assessed by Flow Cytometry — 3.9 fold change — p=0.60